Prenetics Global (PRE) Projected to Post Quarterly Earnings on Monday

Key Points

• Prenetics Global (NASDAQ:PRE) is expected to report quarterly earnings on October 6th, anticipating a loss of ($0.71) per share and revenue of $21.70 million.
• The company recently reported ($0.82) earnings per share with a revenue of $17.68 million, and analysts project EPS of ($3) for the current fiscal year.
• Shares opened at $12.57 with a market cap of $163.16 million, and Wall Street Zen has upgraded Prenetics Global to a "hold" rating.

Prenetics Global (NASDAQ:PRE - Get Free Report) is expected to be issuing its results before the market opens on Monday, October 6th. Analysts expect the company to announce earnings of ($0.71) per share and revenue of $21.70 million for the quarter. Prenetics Global has set its FY 2025 guidance at EPS.

Prenetics Global (NASDAQ:PRE - Get Free Report) last announced its earnings results on Friday, September 12th. The company reported ($0.82) earnings per share for the quarter. The company had revenue of $17.68 million for the quarter. Prenetics Global had a negative return on equity of 31.05% and a negative net margin of 87.92%. On average, analysts expect Prenetics Global to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Prenetics Global Price Performance

Shares of PRE stock opened at $12.57 on Monday. The firm has a market cap of $163.16 million, a PE ratio of -3.15 and a beta of 0.15. The company has a 50-day moving average of $8.74 and a two-hundred day moving average of $7.21. Prenetics Global has a 1-year low of $3.09 and a 1-year high of $13.87.

Analyst Ratings Changes

Separately, Wall Street Zen raised shares of Prenetics Global to a "hold" rating in a research report on Saturday, July 5th. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $9.00.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.